Department of Pharmacy, Erlanger Baroness Hospital, Chattanooga, Tennessee, USA.
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Blood Cancer. 2024 Oct;71(10):e31223. doi: 10.1002/pbc.31223. Epub 2024 Jul 25.
Blinatumomab is a bispecific T-cell engager administered as a 28-day continuous infusion. Infusions can be associated with interruptions requiring support from clinical staff, but the frequency of interventions with outpatient blinatumomab has not been characterized. This study is a single-center, retrospective review of patients who received blinatumomab between December 3, 2014 and October 31, 2021 to determine frequency and type of interventions. Forty patients received blinatumomab for 69 cycles. Clinical staff intervention was required in 31 (45%) cycles, only six (8.7%) cycles needed readmission. Management of outpatient blinatumomab infusions requires education and training of clinical staff and caregivers to quickly troubleshoot interruptions.
Blinatumomab 是一种双特异性 T 细胞衔接器，作为 28 天的连续输注给药。输注可能会中断，需要临床工作人员的支持，但尚未描述门诊使用 blinatumomab 的干预频率。这项研究是对 2014 年 12 月 3 日至 2021 年 10 月 31 日期间接受 blinatumomab 治疗的患者进行的单中心回顾性分析，以确定干预的频率和类型。40 名患者接受了 69 个周期的 blinatumomab 治疗。31 个（45%）周期需要临床工作人员干预，只有 6 个（8.7%）周期需要重新入院。门诊 blinatumomab 输注的管理需要对临床工作人员和护理人员进行教育和培训，以便快速解决中断问题。
